Natera, Inc.'s (NASDAQ:NTRA) CEO and President, Steven Leonard Chapman, has sold a significant portion of his company stock, according to recent filings. The transactions, which took place on May 15, 2024, involved the sale of 6,779 shares of Natera's common stock, generating a total of over $725,000 for Chapman.
The sale was executed in two separate transactions with prices ranging from $106.10 to $108.02 per share. The first batch of 3,459 shares was sold at an average price of $106.5944, while the second batch consisting of 3,320 shares was sold at an average price of $107.5907. Following these sales, Chapman still holds a substantial amount of Natera's shares, with 219,456 shares remaining in his possession.
Investors should note that these sales were carried out under a prearranged 10b5-1 trading plan, which Chapman adopted on December 11, 2023. This plan allows company insiders to set up a predetermined schedule for buying and selling shares to avoid accusations of insider trading.
Natera, headquartered in Austin, Texas, specializes in genetic testing and diagnostics, offering a range of services in women's health, oncology, and organ health. The transactions come at a time when the company continues to innovate in the medical laboratory space, providing cutting-edge solutions for patients and healthcare providers.
The sales were reported through an SEC Form 4 filing, which is a requirement for officers, directors, and significant shareholders in public companies to disclose their transactions in the company's shares. This transparency ensures that the investing public is aware of insider transactions, which can provide insights into the confidence levels of a company's leadership in the business's prospects.
Investors and market watchers typically monitor insider buying and selling patterns as part of their analysis, considering such transactions as one of many factors in their investment decisions.
InvestingPro Insights
As Natera, Inc. (NASDAQ:NTRA) navigates through a period of significant insider transactions, investors are keenly observing the company's financial health and market performance. A glance at the latest real-time data from InvestingPro reveals several key metrics that could be of interest to shareholders and potential investors:
- The company's market capitalization stands at $13.07 billion, reflecting its substantial size within the genetic testing and diagnostics industry.
- Revenue growth has been robust, with a 39.26% increase over the last twelve months as of Q1 2024, indicating a strong expansion in its business operations.
- Despite these positive growth figures, Natera's P/E ratio is currently at -34.25, and analysts do not expect the company to be profitable this year.
InvestingPro Tips shed further light on Natera's financial position and market sentiment:
- Analysts have revised their earnings downwards for the upcoming period, which may suggest caution regarding the company's near-term profitability.
- The company has experienced a high return over the last year, with a 114.46% price total return, signaling strong investor confidence and market performance.
For those looking to delve deeper into Natera's financial landscape, InvestingPro offers a comprehensive suite of additional tips. In fact, there are 13 more InvestingPro Tips available for Natera, which can be accessed by visiting https://www.investing.com/pro/NTRA. These tips provide valuable insights that could help investors make more informed decisions.
Interested readers can take advantage of a special offer: use coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription at InvestingPro. This offer could be particularly beneficial for those tracking insider transactions and seeking a deeper understanding of Natera's financial and market dynamics.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.